A variety of cytokines play a role in the response to an inflammatory stimulus. The interleukin-6 (IL-6)-type cytokines are released in response to tissue injury or an inflammatory stimulus. They act locally and systemically to generate a variety of physiologic responses, principal among them is the acute phase response. The IL-6 type cytokines demonstrate pleiotropy and redundancy of actions. This is made possible by the distinctive characteristics of the IL-6 receptor complex, which contains an ubiquitous subunit that is shared by most IL-6-type cytokines, as well as a cytokine-specific subunit.
Tilg H., Dinarello CA, Mier JWIL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997;18(9):428-432.
2.
Kopf M., Baumann H., Freer G., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994; 368(6469):339-342.
3.
Kushner I., Rzewnicki DLThe acute phase response: general aspects. Baillieres Clin Rheumatol. 1994;8(3):513-530.
4.
Heinrich PC, Castell JV, Andus T.Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621-636.
5.
Kushner I.C-reactive protein in rheumatology. Arthritis Rheum. 1991;34(8):1065-1068.
6.
Black S., Kushner I., Samols D.C-reactive Protein. J Biol Chem. 2004;279(47):48487-48490.
7.
Arredouani MS , Kasran A., Vanoirbeek JA, Berger FG, Baumann H., Ceuppens JLHaptoglobin dampens endotoxin-induced inflammatory effects both. in vitro. and in vivo. Immunology. 2005;114(2):263-271.
8.
Mortensen RF , Zhong W.Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000 ;67(4): 495-500.
9.
Naka T., Nishimoto N., Kishimoto T.The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(3):S233-S242.
10.
Park JY, Pillinger MHInterleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(1):S4-S10.
11.
Cronstein BNInterleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis . 2007; 65(1):S11-S15.
12.
Biffl WL, Moore EE, Moore FA, Carl VS, Kim FJ, Franciose RJInterleukin-6 potentiates neutrophil priming with platelet-activating factor . Arch Surg. 1994;129(11):1131-1136.
13.
Nijsten MW, Hack CE, Helle M., ten Duis HJ, Klasen HJ, Aarden LAInterleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery. 1991 ;109(6):761-767.
14.
Scheller J. , Rose-John S.Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195(4):173-183.
15.
Peng J., Friese P., George JN, Dale GL, Burstein SAAlteration of platelet function in dogs mediated by interleukin-6. Blood. 1994; 83(2):398-403.
16.
Grignani G. , Maiolo A.Cytokines and hemostasis. Haematologica. 2000;85(9):967-972.
17.
Ahad A. Baumann H., Elias J., et al. Interleukin-6-type cytokines in diagnostics and therapeutics: roundtable discussion. Ann N Y Acad Sci . 1995;762:375-387.
18.
Dimopoulou I., Tsagarakis S., Kouyialis AT, et al. Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 concentrations. Crit Care Med. 2004;32(2):404-408.
19.
Kashiwabara M., Miyashita M., Nomura T., et al. Surgical trauma-induced adrenal insufficiency is associated with postoperative inflammatory responses. J Nippon Med Sch. 2007;74(4):274-283.
20.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GPThe pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128(2):127-137.
21.
Chesnokova V., Melmed S.Minireview: neuro-immunoendocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules . Endocrinology. 2002;143(5):1571-1574.
22.
Wasmuth HE, Kunz D., Graf J., et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med. 2004;32(5): 1109-1114.
23.
Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003; 278(16):13740-13746.
24.
Beeton CA, Chatfield D., Brooks RA, Rushton N.Circulating levels of interleukin-6 and its soluble receptor in patients with head injury and fracture. J Bone Joint Surg Br. 2004;86(6): 912-917.
25.
Dekkers PE, Juffermans NP, ten Hove T., de Jonge E., van Deventer SJ, van der Poll T.Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. J Infect Dis . 2000;181(3):1055-1061.
26.
Yahara N., Abe T., Morita K., Tangoku A., Oka M.Comparison of interleukin-6, interleukin-8, and granulocyte colony-stimulating factor production by the peritoneum in laparoscopic and open surgery. Surg Endosc. 2002;16(11):1615-1619.
27.
Ohzato H., Yoshizaki K., Nishimoto N., et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery. 1992;111(2):201-209.
28.
Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215(4):356-362.
29.
Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74(5):1704-1710.
30.
Heinrich PC, Behrmann I., Müller-Newen G., Schaper F., Graeve L.Interleukin-6-type cytokine signalling through the gp130/Jak/ STAT pathway . Biochem J. 1998;334(2):297-314.
Ranieri VM, Suter PM, Tortorella C., et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999;282(1):54-61.
34.
Pan W., Yu C., Hsuchou H., Zhang Y., Kastin AJNeuroinflammation facilitates LIF entry into brain: role of TNF. Am J Physiol Cell Physiol. 2008;294(6):C1436-1442.
35.
Wahl AF, Wallace PMOncostatin M in the anti-inflammatory response. Rev Physiol Biochem Pharmacol. 2003;149:39-52.
36.
Wallace P., MacMaster J., Rillema J., et al. In vivo properties of Oncostatin M. Ann N Y Acad Sci. 1995;762(1):42-54.
37.
Gómez-Lechón MJOncostatin M.: signal transduction and biological activity . Life Sci. 1999;65(20):2019-2030.
38.
Pignatti P. , Ciapponi L., Galle P., et al. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol. 2003;131(2):355-363.
39.
Latchman DSCardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther. 2000;85(1):29-37.
40.
Huising MO, Kruiswijk CP, Flik G.Phylogeny and evolution of class-I helical cytokines. J Endocrinol . 2006;189(1):1-25.
41.
Hamanaka I. , Saito Y., Nishikimi T., et al. Effects of cardiotrophin-1 on hemodynamics and endoc1rine function of the heart. Am J Physiol Heart Circ Physiol. 2000;279(1):H388-H396.
42.
Pulido EJ, Shames BD, Pennica D., et al. Cardiotrophin-1 attenuates endotoxin-induced acute lung injury . J Surg Res. 1999;84(2): 240-246.
43.
Derouet D., Rousseau F., Alfonsi F., et al. Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA. 2004;101(14):4827-4832.
44.
Guillet C., Fourcin M., Chevalier S., Pouplard A., Gascan H.ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock . Ann N Y Acad Sci. 1995;762:407-409.
45.
Schinkel C. , Wick M., Muhr G., Köller M.Analysis of systemic interleukin-11 after major trauma. Shock. 2005;23(1):30-34.
46.
Heizmann O. , Koeller M., Muhr G., Oertli D., Schinkel C.Th1- and Th2-type cytokines in plasma after major trauma. J Trauma. 2008;65(6):1374-1378.
47.
Opal S., Keith J. Jr, Jhung J., et al. Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis. 2003;187(1):70-76.
48.
Kastelein RA , Hunter CA, Cua DJDiscovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221-242.
49.
Villarino AV , Hunter CABiology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther. 2004;6(5):225-233.
50.
Takaoka A., Arai I., Sugimoto M., Yamaguchi A., Tanaka M., Nakaike S.Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis . Eur J Pharmacol. 2005;516(2):180-181.
51.
Dillon SR, Sprecher C., Hammond A., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752-60. Erratum in Nat Immunol . 2005;6(1):114.
52.
Jawa R., Chattopadhyay S., Tracy E., et al. Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages . J Interferon Cytokine Res. 2008;28(4):207-219.
53.
Ip WK, Wong CK, Li ML, et al. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007;122(4):532-541.
54.
Perrigoue JG , Li J., Zaph C., et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007; 204(3):481-487.
55.
Marsik C., Halama T., Cardona F., Schlifke I., Mittermayer F., Jilma B.Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level. Clin Immunol. 2005;114(3):293-298.
56.
Yu X., Kennedy RH, Liu SJJAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes . J Biol Chem. 2002;278(18):16304-16309.
57.
Petersen AM , Pedersen BKThe anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-1162.
58.
May L., Ndubisi M., Patel K., Garcia D.Interleukin-6 chaperones in blood. Ann N Y Acad Sci. 1995;762:120-128.
59.
Sutherland AM, Walley KR, Manocha S., Russell JAThe association of interleukin-6 haplotype clades with mortality in critically ill adults. Arch Intern Med. 2005;165(1):75-82.
60.
Annane D., Sébille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-871. Erratum in JAMA. 2008;300(14):1652.
61.
Sochorova K. , Horvath R., Rozkova D., et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007;109(6):2553-2556.
62.
Krishnan J. , Selvarajoo K., Tsuchiya M., Lee G., Choi S.Toll-like receptor signal transduction. Exp Mol Med. 2007;39(4):421-438.
63.
Schilling D., Thomas K., Nixdorff K., Vogel SN, Fenton MJToll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages. J Immunol. 2002;169(10):5874-5880.
64.
Dissanayake S. , Amith RS, Shahin A.Taenia crassiceps carbohydrates stimulate IL-6 expression in naïve murine macrophages via Toll-like receptors (TLRs) . Mol Immunol. 2004;41(4):391-398.
65.
Ndubuisi MI, Patel K., Rayanade RJ, Mittelman A., May LT, Sehgal PBDistinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol. 1998 ;160(1):494-501.
66.
Bravo J., Heath JKReceptor recognition by gp130 cytokines. EMBO J. 2000;19(11):2399-2411.
67.
Kishimoto T.IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005;28(3):177-186.
68.
http://www.wikipedia.com. Accessed October 14, 2009.
69.
Zvonic S., Baugh JEJr, Arbour-Reily P., Mynatt RL, Stephens JMCross-talk among gp130 cytokines in adipocytes. J Biol Chem . 2005;280(40):33856-33863.
70.
Heinrich PC , Behrmann I., Haan S., Hermanns HM, Müller-Newen G., Schaper F.Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J. 2003;374(pt 1):1-20.
71.
Pathan N., Williams EJ, Oragui EE, Stephens AC, Levin M.Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock. Crit Care Med. 2005;33(8):1839-1844.
72.
Rose-John S.Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol. 2003;50(3): 603-611.
73.
Rose-John S. , Scheller J., Elson G., Jones SAInterleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-236.
74.
Fitzgerald K., O’Neill L., Gearing A., Callard R.Interleukin-6. The cytokine factsbook. London, UK: Academic Press; 2001:69-72.
75.
Walev I., Vollmer P., Palmer M., Bhakdi S., Rose-John S.Pore-forming toxins trigger shedding of receptors for interleukin-6 and lipopolysaccharide . Proc Natl Acad Sci USA. 1996;93(15): 7882-7887.
76.
Taga T., Hibi M., Hirata Y., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58(3):573-581.
77.
Nakajima T. , Yamamoto S., Cheng M., et al. Soluble interleukin-6 receptor is released from receptor-bearing cell lines in vitro. Jpn J Cancer Res. 1992;83(4):373-378.
78.
Jones SA, Horiuchi S., Topley N., Yamamoto N., Fuller GMThe soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43-58.
79.
Campo S., Serlupi-Crescenzi O., Arseni B., et al. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Cytokine . 2005;31(5): 368-374.
80.
Acalovschi D., Wiest T., Hartmann M., et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke. 2003 ;34(8): 1864-1869.
81.
Boulanger MJ , Chow DC, Brevnova EE, Garcia KCHexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/ gp130 complex. Science. 2003 ;300(5628):2101-2104. Erratum in Science. 2003;301:918..
82.
Diveu C., Lak-Hal AH, Froger J., et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw. 2004;15(4):291-302.
83.
http://www.ncbi.nlm.nih.gov/gene. Accessed September 14, 2010.
84.
Corbi P., Rahmati M., Delwail A., et al. Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation. Eur J Cardiothorac Surg. 2000;18(1):98-103.
85.
Andrejko KM , Raj NR, Kim PK, Cereda M., Deutschman CSIL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock. 2008;29(4): 490-496.
86.
Hirano T., Ishihara K., Hibi M.Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19(21): 2548-2556.
87.
Fielding CA , McLoughlin RM, McLeod L., et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol. 2008;181(3):2189-2195.
88.
Sehgal PBParadigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol. 2008;19(4):329-340.
89.
Sehgal PBPlasma membrane rafts and chaperones in cytokine/ STAT signaling. Acta Biochim Pol. 2003;50(3):583-594.
90.
Shah M., Patel K., Fried VA, Sehgal PBInteractions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem. 2002;277(47):45662-45669.
91.
Kushner I., Rzewnicki D., Samols D.What does minor elevation of C-reactive protein signify?Am J Med. 2006;119(2):166.e17-166.e28.
92.
Billiar TR, Curran RD, Williams DL, Kispert PHLiver nonparenchymal cells are stimulated to provide interleukin-6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch Surg. 1992;127(1): 31-36.
93.
Derhaschnig U., Bergmair D., Marsik C., Schlifke I., Wijdenes J., Jilma B.Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med. 2004;32(5): 1136-1140. Erratum in Crit Care Med. 2004;32(8): 1813.
